Every one of those 2 sits in a single category, medical-devices. John Sakys is most often covered alongside Siddhartha Kadia, which appears in 2 of these 2 stories. Across a 7-day span, the pace is roughly 2 stories per week.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about John Sakys
Every one of those 2 sits in a single category, medical-devices. John Sakys is most often covered alongside Siddhartha Kadia, which appears in 2 of these 2 stories. Across a 7-day span, the pace is roughly 2 stories per week. The 5 average consequence score is below the beat benchmark of 5.4 in the same window. Source depth averages 2.5 original sources per story, versus 2.2 across the same-window beat baseline. John Sakys appears in 2 tracked Healthcare stories published from August 11, 2026 through August 17, 2026.
Stories tracked
2
Per week
2
Sources per story
2.5
Computed from the 2 stories linked to this entity, with beat comparisons drawn from all 97 Healthcare stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering John Sakys. Shared-story counts are live from our verified record — not editorial picks.
Mesa Laboratories' Q1 FY2027 shows margin expansion to 64.9% and 19.5% adjusted operating income growth, but its Sterilization and Disinfection Control segment declined 3.6% organically due to fulfillment and delivery execution issues. Clinical genomics was flat as China fell 7%, underscoring uneven healthcare demand.
Mesa Laboratories' Sterilization and Disinfection Control business faces fulfillment bottlenecks that are restraining growth in a $60.1M revenue quarter. New CEO Siddhartha Kadia vows to fix execution problems in a unit critical for hospital sterilization monitoring and infection prevention.